Compare CMP & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | FLGT |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.2M | 697.3M |
| IPO Year | 2003 | 2016 |
| Metric | CMP | FLGT |
|---|---|---|
| Price | $18.66 | $26.96 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $19.67 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 499.5K | 272.3K |
| Earning Date | 12-08-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,243,900,000.00 | $315,549,000.00 |
| Revenue This Year | $4.83 | $16.84 |
| Revenue Next Year | $2.61 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.32 | ★ 13.61 |
| 52 Week Low | $8.60 | $14.57 |
| 52 Week High | $22.69 | $31.04 |
| Indicator | CMP | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 45.89 |
| Support Level | $16.77 | $26.69 |
| Resistance Level | $18.10 | $31.04 |
| Average True Range (ATR) | 1.09 | 0.74 |
| MACD | -0.13 | -0.44 |
| Stochastic Oscillator | 37.55 | 9.29 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.